Palisade Bio Inc (PALI) Stock Price, Quote & News

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement wi...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4900

Website: www.palisadebio.com

Address:

7750 El Camino Real, Suite 2A, Carlsbad, United States

WallStreetBuyDip Jul. 7 at 4:33 PM

I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.

0 · Reply

Kennyk93 Jul. 7 at 12:48 AM

Update: $PALI .7250 GNS 1.43

0 · Reply

bullyboybilll Jul. 1 at 1:48 PM

$PALI 🚀🚀🚀🚀 Verdict At this stage, a negative safety outcome is highly unlikely based on PALI‑2108’s clean early data and favorable PK profile. The real higher-stakes event will come with Phase 1b/2 efficacy and safety in patients, not the initial healthy volunteer cohorts. Would you like me to monitor upcoming trial updates, provide alerts around Phase 1b/2 readouts, or track analyst sentiment shifting as the drug progresses?

2 · Reply

bullyboybilll Jul. 1 at 1:45 PM

$PALI yall must dont know about this 🐢 bullish af

0 · Reply